Skip to main content

Table 1 COVID-19 patients analyzed by CyTOF and Nanostring, divided according to their serum FT3 levels

From: Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies

Pts

Sex

Age

Neoplastic disease

Non-neoplastic diseases

FT3 (pg/ml)

FT4 (ng/ml)

TSH (µIU/ml)

A—Patients with Normal FT3 serum values

 Sand-100

M

68

 

Paroxysmal atrial fibrillation, peptic ulcers with anemia, COPD with pneumothorax in the past; monoclonal gammopathy

1.8

1.2

0.11

 Sand-007

F

88

 

Hypertension

1.8

1.1

0.38

B—Patients with low FT3 serum values

 Sand-003

M

60

 

Hematoma of the right iliopsoas muscle (secondary to therapy with heparin); hemorrhagic liver cyst

1.3

0.8

0.77

 Sand-006

M

74

Chronic lymphocytic leukemia (CLL)

Benign prostatic hypertrophy (BPH); pancreatic cyst

1.2

1.8

0.07

 Sand-011

M

69

Mixed cellularity classical Hodgkin lymphoma (MCcHL)

Gallbladder stones; benign prostatic hypertrophy (BPH)

1

0.9

0.62

 Sand-004

F

69

 

Encephalitis

< 1

1

0.2